| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 997 | 2012 |
| Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 JR Mikhael, D Dingli, V Roy, CB Reeder, FK Buadi, SR Hayman, ... Mayo Clinic Proceedings 88 (4), 360-376, 2013 | 722 | 2013 |
| Efficacy of venetoclax as targeted therapy for relapsed/refractory t (11; 14) multiple myeloma S Kumar, JL Kaufman, C Gasparetto, J Mikhael, R Vij, B Pegourie, ... Blood, The Journal of the American Society of Hematology 130 (22), 2401-2409, 2017 | 560 | 2017 |
| Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group M Cavo, E Terpos, C Nanni, P Moreau, S Lentzsch, S Zweegman, ... The lancet oncology 18 (4), e206-e217, 2017 | 534 | 2017 |
| Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial CB Reeder, DE Reece, V Kukreti, C Chen, S Trudel, J Hentz, B Noble, ... Leukemia 23 (7), 1337-1341, 2009 | 498 | 2009 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 474 | 2016 |
| Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study PG Richardson, DS Siegel, R Vij, CC Hofmeister, R Baz, S Jagannath, ... Blood, The Journal of the American Society of Hematology 123 (12), 1826-1832, 2014 | 460 | 2014 |
| Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis JR Mikhael, SR Schuster, VH Jimenez-Zepeda, N Bello, J Spong, ... Blood, The Journal of the American Society of Hematology 119 (19), 4391-4394, 2012 | 440 | 2012 |
| Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma MQ Lacy, SR Hayman, MA Gertz, A Dispenzieri, F Buadi, S Kumar, ... Journal of Clinical Oncology 27 (30), 5008-5014, 2009 | 435 | 2009 |
| Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines SK Kumar, JR Mikhael, FK Buadi, D Dingli, A Dispenzieri, R Fonseca, ... Mayo Clinic Proceedings 84 (12), 1095-1110, 2009 | 417 | 2009 |
| Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial P Moreau, MA Dimopoulos, J Mikhael, K Yong, M Capra, T Facon, ... The Lancet 397 (10292), 2361-2371, 2021 | 349 | 2021 |
| New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) EM Ocio, PG Richardson, SV Rajkumar, A Palumbo, MV Mateos, ... Leukemia 28 (3), 525-542, 2014 | 310 | 2014 |
| Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline J Mikhael, N Ismaila, MC Cheung, C Costello, MV Dhodapkar, S Kumar, ... Journal of Clinical Oncology 37 (14), 1228-1263, 2019 | 306 | 2019 |
| Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease MQ Lacy, JB Allred, MA Gertz, SR Hayman, KD Short, F Buadi, ... Blood, The Journal of the American Society of Hematology 118 (11), 2970-2975, 2011 | 306 | 2011 |
| Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma KD Short, SV Rajkumar, D Larson, F Buadi, S Hayman, A Dispenzieri, ... Leukemia 25 (6), 906-908, 2011 | 259 | 2011 |
| Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 251 | 2021 |
| Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) MQ Lacy, SR Hayman, MA Gertz, KD Short, A Dispenzieri, S Kumar, ... Leukemia 24 (11), 1934-1939, 2010 | 250 | 2010 |
| Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma YX Zhu, E Braggio, CX Shi, KM Kortuem, LA Bruins, JE Schmidt, ... Blood, The Journal of the American Society of Hematology 124 (4), 536-545, 2014 | 248 | 2014 |
| Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma CB Reeder, DE Reece, V Kukreti, C Chen, S Trudel, K Laumann, J Hentz, ... Blood, The Journal of the American Society of Hematology 115 (16), 3416-3417, 2010 | 224 | 2010 |
| American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and … S Giralt, L Garderet, B Durie, G Cook, G Gahrton, B Bruno, P Hari, ... Biology of Blood and Marrow Transplantation 21 (12), 2039-2051, 2015 | 212 | 2015 |
